* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download The Palliation of End-Stage Heart Disease
Remote ischemic conditioning wikipedia , lookup
Coronary artery disease wikipedia , lookup
Cardiac contractility modulation wikipedia , lookup
Cardiac surgery wikipedia , lookup
Quantium Medical Cardiac Output wikipedia , lookup
Myocardial infarction wikipedia , lookup
Heart failure wikipedia , lookup
Dextro-Transposition of the great arteries wikipedia , lookup
The Palliation of End-Stage Heart Disease Dr. Jana Pilkey MD, FRCP(C) Internal Medicine, Palliative Medicine March 14th, 2007 “It is easier to die of Cancer than Heart or Renal failure” John Hinton (Medical Attending Physician) 1963 Objectives To define Congestive Heart Failure (CHF) To gain an understanding of what a CHF patient experiences at end of life To be familiar with medications used in CHF To employ a symptom-oriented approach to CHF To discuss prognostication in CHF Heart Failure The inability of heart to meet the metabolic demands of the body New York Heart Association (NYHA) Classification – Class 1 – No dyspnea (but low EF on echo) – Class 2 – Dyspnea on strenuous activity – Class 3 – Dyspnea on activities of daily living – Class 4 – Dyspnea at rest Heart Failure NYHA Grade 4 – Dyspnea at rest – Often have hypotension – Clinical features of CHF – Typically EF < 20% (Grade 4 Ventricle) Mechanisms Natural History May develop slowly or suddenly Often ends in sudden death Main cause coronary heart disease Also caused by: – hypertension, alcohol, viruses, metabolic disorders, valvular disease, cardiomyopathies, congenital abnormalities Natural History 1-2% of general population, 20% of elderly (Hauptman 2005) 1M discharged with CHF yearly in U.S. – (Hauptman 2005) Median survival: – grades 3 and 4 - 1 year – grades 1 and 2 - 5 years (Taylor 2003) – 16 months from first hospitalization (Hanratty 2002) Great effect on quality of life Clinical Features Clinical Features Similarities to Cancer – – Dyspnea – Cachexia/weight loss – Lethargy/poor mobility – – – Pain – – Anxiety & depression – – Insomnia & confusion Postural Hypotension Jaundice More infections Polypharmacy Fear of the future O’Brien et al. BMJ 1998 Clinical Features Differences From Cancer – More edema – Predicting death more difficult – Mistaken belief condition more benign than cancer – No local pressure effects – Less anemia Comparison Between Terminal Illnesses (J Pain and Symp Manage, 2006) Symptom Pain Cancer AIDS HD COPD RD 35-96% 63-80% 41-77% 34-77% 47-50% Depression 3-77% 10-82% 9-36% 37-71% 5-61% Delirium 6-93% 30-65% 30-65% 18-32% 18-33% Fatigue 32-90% 54-85% 69-82% 68-80% 73-87% Dyspnea 10-70% 11-62% 60-88% 90-95% 11-62% Anorexia 30-92% 57% 21-41% 35-67% 25-64% Experience of Patients Lung Cancer – Clearer trajectory – able to – – – – plan for death Initially feel well but told you are ill Good understanding of diagnosis and prognosis Relatives anxious Swinging between hope and despair (Murray 2002) Cardiac Failure – Gradual decline, acute – – – – deterioration, sudden death Feel ill but told you are well Little understanding of diagnosis and prognosis Relatives isolated and exhausted Daily grind of hopelessness Experience of Patients Lung Cancer – Cancer takes over life – Treatment dominates life – Feel worse on treatment – Financial benefits accessible – Services available in the community – Care prioritized as “cancer” or “terminal” Cardiac Failure – – – – Much morbidity Shrinking social world Feel better on treatment Less access to financial benefits – Services less available in the community – Less priority as “chronic illness” Classic Pharmacologic Management Ace-I (Angiotensin II antagonists) (HOPE Trial) B- blockers (US Carvedilol Study, CIBIS II, Merit, BEST, COPERNICUS) Diuretics / Spironolactone (RALES trial) Digoxin (DIG Trial) Opioids Pharmacologic Management Drug NYHA 1 NYHA 2 NYHA 3 NYHA 4 Survival Hospital Functional Admits Status Diuretic X ACE-I Spironolactone X X Bblocker X Digoxin X Oxford 2002 Issues in Palliative Care Perceived inability of palliative care to manage Perceived unwillingness of cardiology to seek help (Hanratty 2002) Lack of support networks and communication Prognostication difficult Resuscitation difficult issue – DNR written on 5% (47% in Ca, 52% in AIDS) – DNR wanted by patient in 23% (40% later changed minds) (Gibbs 2002) Issues in Palliative Care Hospitalization only improves symptoms in 35-40% (Ward, 2002) Only 4% of patients dying of CHF get palliative care (40% in cancer pts) (Gibbs, 2002) Average performance status score of hospice admissions is 32 (range 50-10) (Zambroski, 2005) Issues in Palliative Care Severe symptoms in last 48-72 hrs prior to death (SUPPORT study) – Breathlessness 66% – Pain 41% – Severe confusion 15% Regional study of Care of the Dying (RSCD) study – – – – Dyspnea 50% Pain 50% Low mood 59% Anxiety 45% In several studies – pysch symptoms most distressing Symptom Oriented Palliation Pain Management – Pain of angina – 41-77% (metanalysis 2006) – Pain inadequately dealt with in 90% (Gibbs 2002) – Opioids – Anti-anginals – Revascularization – TENS, Spinal cord stimulators Symptom Oriented Palliation Dyspnea – Oxygen – CHF medications – Opioids – Other Symptom Oriented Palliation Edema – Monitor weight regularly – Weight loss 0.5-1kg/day – Diuretics – Fluid restriction – Mild salt restriction – Elevate lower limbs Symptom Oriented Palliation Lightheadedness – Check for postural hypotension – Reassess drugs – Exclude arrhythmia – Reassure and educate Symptom Oriented Palliation Muscle wasting and fatigue – Cachexia occurs in 50% – Physiotherapy – Exercise – if possible – Assess diet and energy intake – Review medications Symptom Oriented Palliation Nausea, taste disturbance, anorexia – Reduced perfusion of intestines, sympathetics – Check chemistry (renal, liver) – Review meds – Frequent small meals – Supplement vitamins – Consider pro-motility agents Symptom Oriented Palliation Depression and Anxiety – Regular assessment – Exercise program – Relaxation exercises – Antidepressants – Consider nocturnal opioid +/- benzodiazipine Implantable Cardioverter Defibrillators and Pacemakers Leave Pacemakers intact Turn off/disable ICD’s – No discussion about turning off ICD in 73% of pts prior to last hours of life (Goldstein, 2004) – 8% of patients receive shocks in the minutes before death (Goldstein, 2004) – Plan ahead ! Inform Funeral Home Prognostication Very difficult to prognosticate Markers of poor prognosis (< 6 months) – Sodium: – – – – – – mean of 164 days if < 137, 373 days if > 137 Liver failure, renal failure, delirium Unable to tolerate ACE-I due to bp NYHA Class 4 EF < 20% Frequent hospitalizations Cachexia (Hauptman 2005, Taylor 2003, Ward 2002) Prognostication NYHA Class 1 Year Mortality I 5-10% II-III 15-30% IV 50-60% Case Study 90 y.o. female admitted to RGH for CHF and COPD with chest pain and dyspnea Hr 98, rr 28, bp 96/64 Na 134, K 4.7, Creat 130, Urea 24 Hgb 110 EF 18% Prognosis?? CHF Risk Model (Canadian Cardiovascualr Outcomes Research Team, JAMA 2003) Age (year) Respiratory Rate (breaths/min) (minimal 20;maximal 45) Systolic blood pressure (mmHg) Blood Urea Nitrogen ( mmol/L) Sodium Concentration <136 mEq/L Yes No Cerebrovascular Disease Yes No Dementia Yes No COPD Yes No Hepatic Cirrhosis Yes No Cancer Yes No Hemoglobin <100 g/L (not required for 30-day Score) Yes No CHF Risk Model Our patient has a score of 127 30-Day Score 30-Day Mortality Rate (%) One-Year Score One-Year Mortality Rate (%) 60 0.4 60 7.8 61-90 3.4 61-90 12.9 91-120 12.2 91-120 32.5 121-150 32.7 121-150 59.3 >150 59.0 >150 78.8 Clinical Assessment Document ventricular function, administer medical therapy Address symptoms, discuss prognosis, involve MDT Progression Reassessment Reassess and treat exacerbating factors Readdress symptoms, reassess goals of care Increase involvement of MDT Consider advanced therapeutic options Ineligible or Declines Hospice Care Generally includes medical and symptom treatment Possibly inotropic support Summary CHF has a very poor prognosis Often need multiple medications for symptom control Palliative care can be of help in CHF Need multidisciplinary team Do we have the resources to palliate CHF?? References Ward, Christopher. The Need For Palliative Care in the Management of Heart Failure. Heart 2002; 87:294-8. Murray, Scott. Dying of Lung Cancer or Cardiac Failure: Prospective Qualitative Interview Study of Patients and Their Carers in the Community. BMJ. 2002; 325:929-34 Gibbs, JSR. Living With and Dying From Heart Failure: The role of Palliative Care. Heart 2002; 88; 36-39. Hauptman, Paul. Integrating Palliative Care Into Heart Failure Care. Arch Intern Med. 2005; 165; 374-8. Seamark, David. Deaths From Heart Failure in General Practice: Implications for Palliative Care. Pall Med; 2002; 16: 495-8. Talyor, George. A Clinician’s Guide to Palliative Care. Blckwell Science. 2003: 47-75. References Zambroski, Cheryl. Patients With Heart Failure Who Die in Hospice. AM Heart J 2005; 149:558-64. Pantilat, Steven. Palliative Care for Patients with Heart Failure. JAMA, 2004; 291: 2476-82. Hanratty, Barbara. Doctors’ Perceptions of Palliative Care for Heart Failure: Focus Group Study. BMJ 2002:325: 581-585. Nanas John. Long-term Intermittent Dobutamine Infusion, Combined with Oral Amiodarone for End-Stage Heart Failure. Chest 2004; 125: 1198-1204. Lopez-Candales, Angel. Need for Hospice and Palliative Care Services in Patients with End-Stage Hearat Failure Treated with Intermittent Infusion of Inotropes. Clin. Cardio. 2004, 27, 23-28. Goldstein, NF.Management of implantable cardioverter defibrillators in end-oflife care.Ann Intern Med. 2004 Dec 7;141(11):835-8.